{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:53:26Z","timestamp":1793148806315,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-02031-0","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:26:43Z","timestamp":1768552003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives"],"prefix":"10.1007","volume":"26","author":[{"given":"Xiaoli","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasi","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"3","key":"2031_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2031_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","volume":"17","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245\u201361.","journal-title":"Nat Rev Nephrol"},{"key":"2031_CR3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178915","author":"P Barata","year":"2024","unstructured":"Barata P, Gulati S, Elliott A, et al. Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles. J Clin Invest. 2024;134(11):e178915. Published 2024 Apr 23. doi:10.1172\/JCI178915","journal-title":"J Clin Invest"},{"issue":"5","key":"2031_CR4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00345-022-03960-1","volume":"40","author":"V Stuhler","year":"2022","unstructured":"Stuhler V, Herrmann L, Maas M, Walz S, Rausch S, Stenzl A, et al. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. World J Urol. 2022;40(5):1175\u201383.","journal-title":"World J Urol"},{"issue":"1","key":"2031_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1586\/14737140.8.1.63","volume":"8","author":"WK Rathmell","year":"2008","unstructured":"Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther. 2008;8(1):63\u201373.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2031_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccell.2022.12.001","volume":"41","author":"Y Li","year":"2023","unstructured":"Li Y, Lih TM, Dhanasekaran SM, Mannan R, Chen L, Cieslik M, et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell. 2023;41(1):139\u201363. e17.","journal-title":"Cancer Cell"},{"issue":"12","key":"2031_CR7","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","volume":"24","author":"YW Chen","year":"2023","unstructured":"Chen YW, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, et al. Treatment landscape of renal cell carcinoma. Curr Treat Options Oncol. 2023;24(12):1889\u2013916.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"2031_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/oncolo\/oyab056","volume":"27","author":"S Gulati","year":"2022","unstructured":"Gulati S, Labaki C, Karachaliou GS, Choueiri TK, Zhang T. First-line treatments for metastatic clear cell renal cell carcinoma: an ever-enlarging landscape. Oncologist. 2022;27(2):125\u201334.","journal-title":"Oncologist"},{"issue":"1","key":"2031_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313\u201326. e5.","journal-title":"Cell Rep"},{"key":"2031_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003231","author":"MR Franklin","year":"2022","unstructured":"Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunother Cancer. 2022;10(1):e003231. doi:10.1136\/jitc-2021-003231","journal-title":"J Immunother Cancer"},{"key":"2031_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02965","volume":"10","author":"P Dobosz","year":"2019","unstructured":"Dobosz P, Dzieciatkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965.","journal-title":"Front Immunol"},{"key":"2031_CR12","doi-asserted-by":"publisher","first-page":"1490129","DOI":"10.3389\/fimmu.2024.1490129","volume":"15","author":"D Zhang","year":"2024","unstructured":"Zhang D, Zhao J, Zhang Y, Jiang H, Liu D. Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity. Front Immunol. 2024;15:1490129.","journal-title":"Front Immunol"},{"issue":"1","key":"2031_CR13","doi-asserted-by":"publisher","first-page":"2261264","DOI":"10.1080\/2162402X.2023.2261264","volume":"12","author":"P Reid","year":"2023","unstructured":"Reid P, Sandigursky S, Song J, Lopez-Olivo MA, Safa H, Cytryn S, et al. Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology. 2023;12(1):2261264.","journal-title":"Oncoimmunology"},{"issue":"19","key":"2031_CR14","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced Renal-Cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"9","key":"2031_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1200\/JCO.20.02365","volume":"39","author":"DF McDermott","year":"2021","unstructured":"McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029\u201339.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2031_CR16","doi-asserted-by":"publisher","first-page":"2193528","DOI":"10.1080\/21645515.2023.2193528","volume":"19","author":"G Gebrael","year":"2023","unstructured":"Gebrael G, Sahu KK, Agarwal N, Maughan BL. Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. Hum Vaccin Immunother. 2023;19(1):2193528.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"2031_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/biomedicines10020251","volume":"10","author":"IH Kim","year":"2022","unstructured":"Kim IH, Lee HJ. The frontline immunotherapy-based treatment of advanced clear cell renal cell carcinoma: current evidence and clinical perspective. Biomedicines. 2022;10(2):251.","journal-title":"Biomedicines"},{"issue":"11","key":"2031_CR18","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir NM, Albiges L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024;35(11):1026\u201338.","journal-title":"Ann Oncol"},{"issue":"5","key":"2031_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","volume":"23","author":"YA Vano","year":"2022","unstructured":"Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, et al. <article-title update=\u201cadded\u201d>Nivolumab, nivolumab\u2013ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):612\u201324.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2031_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","volume":"84","author":"ER Plimack","year":"2023","unstructured":"Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur Urol. 2023;84(5):449\u201354.","journal-title":"Eur Urol"},{"key":"2031_CR21","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Escudier B, Burotto M, Powles T, Apolo AB, Bourlon MT, et al. Final analysis of nivolumab plus Cabozantinib for advanced renal cell carcinoma from the randomized phase III checkmate 9ER trial. Annals of oncology. official journal of the European Society for Medical Oncology; 2025.","DOI":"10.1016\/j.annonc.2025.09.006"},{"issue":"14","key":"2031_CR22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u2013300.","journal-title":"N Engl J Med"},{"issue":"4","key":"2031_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.21037\/tau-23-647","volume":"13","author":"Y Tasaki","year":"2024","unstructured":"Tasaki Y, Hamamoto S, Furukawa-Hibi Y, Yasui T. Effectiveness of switch therapy from tyrosine kinase inhibitors to immune checkpoint inhibitors: the need for biomarkers to establish treatment strategies in patients with metastatic renal cell carcinoma. Transl Androl Urol. 2024;13(4):631\u20134.","journal-title":"Transl Androl Urol"},{"issue":"3","key":"2031_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.clgc.2019.11.016","volume":"18","author":"A Varkaris","year":"2020","unstructured":"Varkaris A, Xu W, Davis RB, Healy B, McDermott DF. Combining immune checkpoint and VEGFR Inhibition in favorable risk and elderly patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2020;18(3):179\u201384. e3.","journal-title":"Clin Genitourin Cancer"},{"issue":"19","key":"2031_CR25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","volume":"388","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, et al. Cabozantinib plus nivolumab and ipilimumab in Renal-Cell carcinoma. N Engl J Med. 2023;388(19):1767\u201378.","journal-title":"N Engl J Med"},{"issue":"9","key":"2031_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","volume":"23","author":"T Powles","year":"2022","unstructured":"Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(9):1133\u201344.","journal-title":"Lancet Oncol"},{"issue":"10358","key":"2031_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","volume":"400","author":"SK Pal","year":"2022","unstructured":"Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022;400(10358):1103\u201316.","journal-title":"Lancet"},{"issue":"10379","key":"2031_CR28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Russo P, Grunwald V, Tomita Y, Zurawski B, Parikh O, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023;401(10379):821\u201332.","journal-title":"Lancet"},{"issue":"8","key":"2031_CR29","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","volume":"25","author":"ME Allaf","year":"2024","unstructured":"Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25(8):1038\u201352.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2031_CR30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021;27(5):802\u20135.","journal-title":"Nat Med"},{"issue":"6","key":"2031_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102235","volume":"22","author":"F Sidhom","year":"2024","unstructured":"Sidhom F, Patel S, Desai A, Basu A. High sensitivity circulating tumor-DNA assays in renal cell carcinoma-are we there yet? Clin Genitourin Cancer. 2024;22(6):102235.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2031_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","volume":"62","author":"WK Han","year":"2002","unstructured":"Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237\u201344.","journal-title":"Kidney Int"},{"issue":"10","key":"2031_CR33","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Rini BI, McDermott DF, Aren Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370\u201385.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2031_CR34","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116\u201327.","journal-title":"N Engl J Med"},{"issue":"14","key":"2031_CR35","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"10397","key":"2031_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, Albiges L, Tomczak P, Suarez C, Voss MH, de Velasco G, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;402(10397):185\u201395.","journal-title":"Lancet"},{"issue":"10460","key":"2031_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","volume":"404","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Albiges L, Barthelemy P, Iacovelli R, Emambux S, Molina-Cerrillo J, et al. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet. 2024;404(10460):1309\u201320.","journal-title":"Lancet"},{"issue":"16","key":"2031_CR38","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1002\/cam4.4679","volume":"11","author":"Y Yang","year":"2022","unstructured":"Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, et al. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022;11(16):3106\u201314.","journal-title":"Cancer Med"},{"issue":"6","key":"2031_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/imt-2023-0267","volume":"16","author":"Y Jani","year":"2024","unstructured":"Jani Y, Jansen CS, Gerke MB, Bilen MA. Established and emerging biomarkers of immunotherapy in renal cell carcinoma. Immunotherapy. 2024;16(6):405\u201326.","journal-title":"Immunotherapy"},{"key":"2031_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13195738","author":"S Compagno","year":"2024","unstructured":"Compagno S, Casadio C, Galvani L, Rosellini M, Marchetti A, Tassinari E, et al. Novel immune checkpoint inhibitor targets in advanced or metastatic renal cell carcinoma: state of the art and future perspectives. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13195738.","journal-title":"J Clin Med"},{"key":"2031_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17061012","author":"AG El-Shemi","year":"2025","unstructured":"El-Shemi AG, Alqurashi A, Abdulrahman JA, et al. IL-10-Directed Cancer Immunotherapy: Preclinical Advances, Clinical Insights, and Future Perspectives. Cancers (Basel). 2025;17(6):1012. Published 2025 Mar 17. doi:10.3390\/cancers17061012","journal-title":"Cancers"},{"issue":"1","key":"2031_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"S Muhammad","year":"2023","unstructured":"Muhammad S, Fan T, Hai Y, Gao Y, He J. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer. 2023;22(1):121.","journal-title":"Mol Cancer"},{"issue":"8","key":"2031_CR43","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","volume":"10","author":"A Diab","year":"2020","unstructured":"Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, et al. Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov. 2020;10(8):1158\u201373.","journal-title":"Cancer Discov"},{"key":"2031_CR44","doi-asserted-by":"publisher","first-page":"575597","DOI":"10.3389\/fimmu.2020.575597","volume":"11","author":"KG Nguyen","year":"2020","unstructured":"Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol. 2020;11:575597.","journal-title":"Front Immunol"},{"key":"2031_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005813","author":"J Strauss","year":"2023","unstructured":"Strauss J, Deville JL, Sznol M, Ravaud A, Maruzzo M, Pachynski RK, et al. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-005813.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2031_CR46","doi-asserted-by":"publisher","first-page":"e006346","DOI":"10.1136\/jitc-2022-006346","volume":"11","author":"M Sznol","year":"2023","unstructured":"Sznol M, Rizvi N. Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. J Immunother Cancer. 2023;11(1):e006346.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2031_CR47","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","volume":"14","author":"X Qin","year":"2024","unstructured":"Qin X, Ning W, Liu H, Liu X, Luo W, Xia N. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy. Acta Pharm Sin B. 2024;14(6):2361\u201377.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"2031_CR48","first-page":"34","volume":"13","author":"L Meng","year":"2024","unstructured":"Meng L, Collier KA, Wang P, Li Z, Monk P, Mortazavi A, et al. Emerg Immunotherapy Approaches Adv Clear Cell Ren Cell Carcinoma. 2024;13(1):34.","journal-title":"Emerg Immunotherapy Approaches Adv Clear Cell Ren Cell Carcinoma"},{"issue":"10_Supplement","key":"2031_CR49","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-25-B006","volume":"24","author":"SK Pal","year":"2025","unstructured":"Pal SK, Sweiss RF, Kotecha R, Runcie K, Bilen M, Msaouel P, et al. Abstract B006: preliminary phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). Mol Cancer Ther. 2025;24(10_Supplement):B006-B.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2031_CR50","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25(5):479\u201389.","journal-title":"Curr Oncol Rep"},{"issue":"8_Supplement","key":"2031_CR51","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT011","volume":"83","author":"S Srour","year":"2023","unstructured":"Srour S, Kotecha R, Curti B, et al. Abstract CT011: a phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)[J]. Cancer Research, 2023, 83(8_Supplement): CT011-CT011","journal-title":"Cancer Res"},{"key":"2031_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020146","author":"C Lonez","year":"2024","unstructured":"Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells. 2024;13(2):146. Published 2024 Jan 12. doi:10.3390\/cells1302014","journal-title":"Cells"},{"issue":"1","key":"2031_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.trecan.2020.09.002","volume":"7","author":"M Ecsedi","year":"2021","unstructured":"Ecsedi M, McAfee MS, Chapuis AG. The anticancer potential of T cell Receptor-Engineered T cells. Trends Cancer. 2021;7(1):48\u201356.","journal-title":"Trends Cancer"},{"issue":"4_suppl","key":"2031_CR54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1200\/JCO.2024.42.4_suppl.435","volume":"42","author":"R Nadal","year":"2024","unstructured":"Nadal R, Barisic S, Scurti GM, Cherkasova E, Chen L, Wood K, et al. Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol. 2024;42(4_suppl):435.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2031_CR55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3095","volume":"34","author":"S Gupta","year":"2016","unstructured":"Gupta S, Tavakkoli F, Soukharev S, Gao G, Morris SR, Miller JS. A phase 1, first-time-in-human study of MEDI9197, a TLR7\/8 agonist, administered intratumorally in subjects with a solid tumor cancer. J Clin Oncol. 2016;34(15_suppl):TPS3095-TPS.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2031_CR56","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.4161\/21645515.2014.983857","volume":"10","author":"A Kirner","year":"2014","unstructured":"Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother. 2014;10(11):3179\u201389.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"2031_CR57","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","volume":"26","author":"RA Figlin","year":"2020","unstructured":"Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, et al. Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2020;26(10):2327\u201336.","journal-title":"Clin Cancer Res"},{"issue":"16_Supplement","key":"2031_CR58","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT301","volume":"80","author":"JS Lopez","year":"2020","unstructured":"Lopez JS, Camidge R, Iafolla M, Rottey S, Schuler M, Hellmann M, et al. Abstract CT301: a phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Res. 2020;80(16_Supplement):CT301-CT.","journal-title":"Cancer Res"},{"issue":"1","key":"2031_CR59","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","volume":"11","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang S, Sun H, Xu L. The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma. Cell Death Discov. 2025;11(1):186.","journal-title":"Cell Death Discov"},{"issue":"4","key":"2031_CR60","doi-asserted-by":"publisher","first-page":"112183","DOI":"10.1016\/j.isci.2025.112183","volume":"28","author":"Z Xu","year":"2025","unstructured":"Xu Z, Dong Y, Cui K, Hu B, Lu Y, Liu X, et al. Role of the circular RNAs\/microRNA\/messenger RNA axis in renal cell carcinoma: from gene regulation to metabolism and immunity. iScience. 2025;28(4):112183.","journal-title":"iScience"},{"issue":"19","key":"2031_CR61","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2217\/fon-2023-0871","volume":"20","author":"N Kaplinsky","year":"2024","unstructured":"Kaplinsky N, Williams K, Watkins D, Adams M, Stanbery L, Nemunaitis J. Regulatory role of CD39 and CD73 in tumor immunity. Future Oncol (London England). 2024;20(19):1367\u201380.","journal-title":"Future Oncol (London England)"},{"issue":"1","key":"2031_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","volume":"10","author":"L Fong","year":"2020","unstructured":"Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, et al. Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discov. 2020;10(1):40\u201353.","journal-title":"Cancer Discov"},{"key":"2031_CR63","doi-asserted-by":"publisher","DOI":"10.1177\/11786469231185102","volume":"16","author":"A Shadboorestan","year":"2023","unstructured":"Shadboorestan A, Koual M, Dairou J, Coumoul X. The role of the kynurenine\/AhR pathway in diseases related to metabolism and cancer. Int J Tryptophan Res. 2023;16:11786469231185102.","journal-title":"Int J Tryptophan Res"},{"key":"2031_CR64","doi-asserted-by":"publisher","first-page":"101573","DOI":"10.1016\/j.arr.2022.101573","volume":"75","author":"A Salminen","year":"2022","unstructured":"Salminen A. Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process. Ageing Res Rev. 2022;75:101573.","journal-title":"Ageing Res Rev"},{"key":"2031_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00423","volume":"8","author":"T Komiya","year":"2018","unstructured":"Komiya T, Huang CH. Updates in the clinical development of epacadostat and other indoleamine 2,3-dioxygenase 1 inhibitors (IDO1) for human cancers. Front Oncol. 2018;8:423.","journal-title":"Front Oncol"},{"issue":"5","key":"2031_CR66","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","volume":"25","author":"BW Labadie","year":"2019","unstructured":"Labadie BW, Bao R, Luke JJ. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin Cancer Research: Official J Am Association Cancer Res. 2019;25(5):1462\u201371.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"2031_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-017-0458-0","volume":"18","author":"P Ghatalia","year":"2017","unstructured":"Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint inhibitors for the treatment of renal cell carcinoma. Curr Treat Options Oncol. 2017;18(1):7.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2031_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7(1):331.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"2031_CR69","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1007\/s12325-019-01051-z","volume":"36","author":"S Arora","year":"2019","unstructured":"Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Therapy. 2019;36(10):2638\u201378.","journal-title":"Adv Therapy"},{"key":"2031_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004780","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Jegede OA, Haas NB, et al. Phase II Study of Nivolumab and Salvage Nivolumab\/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022;40(25):2913-2923. doi:10.1200\/JCO.21.02938","journal-title":"J Immunother Cancer"},{"issue":"18","key":"2031_CR71","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cncr.33033","volume":"126","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156\u201367.","journal-title":"Cancer"},{"issue":"4","key":"2031_CR72","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","volume":"36","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, et al. Avelumab\u2009+\u2009axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol. 2025;36(4):387\u201392.","journal-title":"Ann Oncol"},{"issue":"7","key":"2031_CR73","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1159\/000515441","volume":"99","author":"N Hirshoren","year":"2021","unstructured":"Hirshoren N, Al-Kharouf I, Weinberger JM, Eliashar R, Popovtzer A, Knaanie A, et al. Spatial intratumoral heterogeneity expression of PD-L1 antigen in head and neck squamous cell carcinoma. Oncology. 2021;99(7):464\u201370.","journal-title":"Oncology"},{"issue":"24","key":"2031_CR74","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","volume":"26","author":"KI Zhou","year":"2020","unstructured":"Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020;26(24):6453\u201363.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2031_CR75","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.eururo.2021.01.003","volume":"79","author":"T Powles","year":"2021","unstructured":"Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, et al. Efficacy and safety of atezolizumab plus bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in IMmotion150: a randomized phase 2 clinical trial. Eur Urol. 2021;79(5):665\u201373.","journal-title":"Eur Urol"},{"issue":"23","key":"2031_CR76","doi-asserted-by":"publisher","first-page":"13753","DOI":"10.18632\/aging.205261","volume":"15","author":"Q Chang","year":"2023","unstructured":"Chang Q, Sun J, Zhao S, Li L, Zhang N, Yan L, et al. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to nivolumab in patients with ccrcc: a tumor marker prognostic study. Aging. 2023;15(23):13753\u201375.","journal-title":"Aging"},{"issue":"4","key":"2031_CR77","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ajur.2021.05.013","volume":"8","author":"S Gulati","year":"2021","unstructured":"Gulati S, Vogelzang NJ. Biomarkers in renal cell carcinoma: are we there yet? Asian J Urol. 2021;8(4):362\u201375.","journal-title":"Asian J Urol"},{"issue":"11","key":"2031_CR78","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","volume":"26","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. Avelumab plus axitinib versus Sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nat Med. 2020;26(11):1733\u201341.","journal-title":"Nat Med"},{"issue":"4","key":"2031_CR79","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","volume":"18","author":"DA Braun","year":"2021","unstructured":"Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021;18(4):199\u2013214.","journal-title":"Nat Rev Clin Oncol"},{"key":"2031_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008125","author":"JM Versluis","year":"2024","unstructured":"Versluis JM, Blankenstein SA, Dimitriadis P, et al. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma. J Immunother Cancer. 2024;12(4):e008125. Published 2024 Apr 27. doi:10.1136\/jitc-2023-008125IF: 10.6 Q1","journal-title":"J Immunother Cancer"},{"key":"2031_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007180","author":"H Komuro","year":"2023","unstructured":"Komuro H, Shinohara S, Fukushima Y, Demachi-Okamura A, Muraoka D, Masago K, et al. Single-cell sequencing on CD8(+) TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer\/testis antigen in non-small cell lung cancer. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007180.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2031_CR82","first-page":"541","volume":"12","author":"W Zhu","year":"2023","unstructured":"Zhu W, Li Y, Han M, Jiang J. Regulatory mechanisms and reversal of CD8(+)T cell exhaustion: a literature review. Biology (Basel). 2023;12(4):541.","journal-title":"Biology (Basel)"},{"issue":"4","key":"2031_CR83","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/PAI.0000000000001186","volume":"32","author":"Y Bas","year":"2024","unstructured":"Bas Y, Yilmaz B, Acar SF, Karadag I. Programmed cell death ligand 1 expression in CD163\u2009+\u2009tumor-associated macrophages in cancer gland rupture microenvironment. Appl Immunohistochem Mol Morphol. 2024;32(4):176\u201382.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"328","key":"2031_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2031_CR85","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/2159-8290.CD-24-0991","volume":"15","author":"MB Hugaboom","year":"2025","unstructured":"Hugaboom MB, Wirth LV, Street K, Ruthen N, Jegede OA, Schindler NR, et al. Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Cancer Discov. 2025;15(5):948\u201368.","journal-title":"Cancer Discov"},{"issue":"3","key":"2031_CR86","first-page":"517","volume":"6","author":"S Astore","year":"2023","unstructured":"Astore S, Baciarello G, Cerbone L, Calabro F. Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma. Cancer Drug Resist (Alhambra Calif). 2023;6(3):517\u201346.","journal-title":"Cancer Drug Resist (Alhambra Calif)"},{"issue":"5","key":"2031_CR87","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"1","key":"2031_CR88","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"key":"2031_CR89","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3389\/fimmu.2016.00621","volume":"7","author":"SA Hendry","year":"2016","unstructured":"Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB. The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. 2016;7:621.","journal-title":"Front Immunol"},{"key":"2031_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113852","volume":"176","author":"ML Tan","year":"2021","unstructured":"Tan ML, Ling L, Fischbach C. Engineering strategies to capture the biological and biophysical tumor microenvironment in vitro. Adv Drug Deliv Rev. 2021;176:113852.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2031_CR91","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"3","key":"2031_CR92","doi-asserted-by":"publisher","first-page":"e472902","DOI":"10.1200\/EDBK-25-472902","volume":"45","author":"A Elkrief","year":"2025","unstructured":"Elkrief A, Routy B, Derosa L, Bolte L, Wargo JA, McQuade JL, et al. Gut microbiota in immuno-oncology: a practical guide for medical oncologists with a focus on antibiotics stewardship. Am Soc Clin Oncol Educ Book. 2025;45(3):e472902.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-02031-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-02031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-02031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:02:59Z","timestamp":1769569379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-02031-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2031"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-02031-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}